Dublin, Nov. 23, 2021 (GLOBE NEWSWIRE) -- The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
This report describes the latest concepts of pathomechanisms of pain as a basis for the management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging.
Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal anti-inflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, an N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain.
Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan.
Drug delivery is an important consideration in pain treatment. Controlled release preparations provide a steady delivery of analgesics. Well-known non-injection methods such as transdermal, pulmonary, and intranasal applications have been used. Topical analgesics and local anesthetics are also available. Devices such as implanted pumps are used for the delivery of drugs such as opioids intrathecally (introduction into spinal subarachnoid space by lumbar puncture) in patients with cancer pain.
The wide variety of drugs in development includes opioid receptor ligands, bradykinin antagonists, mPGES-1 inhibitors, glutamate receptor antagonists, substance P and neurokinin receptor antagonists, norepinephrine transporter inhibitors, P2X2 neuron receptor antagonists and nitric oxide-based analgesics. A number of cannabinoids are also in development for pain.
Fish-derived tetrodotoxin was initially focused on an indication of opiate addiction withdrawal but is found to have an analgesic action as well. Cone shells contain therapeutically useful peptides including the conotoxins, and one such peptide, ziconotide, has been approved. Various cell and gene therapies are also being developed for the management of pain.
Advances in molecular and biological techniques are markedly advancing our understanding of pain. Understanding the pathophysiology of pain is an important factor in the discovery of rational therapies for pain. Advances in pharmacogenomics and pharmacogenetics are enabling the development of personalized approaches to the management of pain.
The worldwide analgesic markets were analyzed for the year 2020 and projected to 2030. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. The report is supplemented with 78 tables, 25 figures, and 600 selected references to the literature.
Epidemiological basis of pain markets
Irritable bowel syndrome
Chronic pelvic pain
Chronic pain due to traumatic brain injury
Economics of pain
Pain as a driver of healthcare costs
Disability and financial loss through pain in the US
Targeted delivery of analgesics for cancer pain
Pain markets based on painful conditions
The cancer pain market
The arthritis pain market
Postsurgical pain market
The backache market
The headache market
Neuropathic pain market
Pain markets based on drugs
Nonsteroidal antiinflammatory drugs
Transdermal pain therapeutics
Antiepileptic drugs as analgesics
Hospital vs retail share of pain market
Hospital versus retail opioid market
Devices for pain
Pain markets according to geographical areas
Cost effectiveness of various approaches
Unfulfilled R&D needs in pain therapy
Under treatment of pain
Unfulfilled needs in drug development for chronic pain
Strategies for developing pain markets
Finding alternatives to intrathecal administration for chronic pain
Development of other applications of analgesic drugs
Partnership of patients, pharmacists and companies
Factors that may influence future pain markets
Drivers of pain markets
Public surveys as indicators of impact of pain on people
Effect of regulatory reviews on markets for pain products
Novel versus older therapies for pain
Key Topics Covered:
1. Basic Aspects of Pain
2. Assessment of Pain and Analgesics
3. Pharmacotherapy of Pain
4. Management of Pain
5. Drug Delivery for Pain
6. Drug Development for Pain
7. Safety, Regulatory and Legal issues of pain management
8. Pain Markets
9. Future of Pain Therapeutics
10. Companies Involved in Pain Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/a9iyv4
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900